May 24, 2016 10:11 AM IST
These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.
- Mar 28, 2016 04:04 PM IST
Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.
- Mar 17, 2016 10:00 AM IST
Highlighting that the insulin market currently has just a handful of players and provides huge scope for growth, Kiran Mazumdar Shaw, CMD of Biocon says, the company will be filing its first insulin analogue dossier in FY17.
- Feb 15, 2016 11:24 AM IST
Kiran Mazumdar-Shaw, Chairman of the company, expects the company to soon win approval in the US as well.
- Feb 05, 2016 10:30 AM IST
The US government‘s decision to not allow overseas pharmaceutical companies to import active pharmaceutical ingredient (API) applies to only one particular anti retroviral drug and is not a blanket ban, Biocon CMD Kiran Mazumdar-Shaw said.
- Dec 10, 2015 10:00 AM IST
Speaking to CNBC-TV18, Dr Arun Chandavarkar, CEO & Joint MD, Biocon says that the company is also looking to introduce its biosimilars and insulin portfolio in the UAE.
- Nov 23, 2015 09:53 PM IST
On Friday, the Central Bureau for Direct Taxes (CBDT) proposed a roadmap to bring corporate tax down from the current 30 percent to 25 percent by doing away with tax breaks to India Inc.
- Sep 15, 2015 10:26 AM IST
In an interview with CNBC-TV18, Peter Bains, CEO of Syngene International says that the company will invest nearly USD 100 million for a new plant in Mangalore, which will become functional in 2018.
- Aug 20, 2015 05:31 PM IST
Kiran Mazumdar Shaw, Chairman and MD, Biocon believes India‘s innovation led growth story is what investors are buying into but foreign investors need predictability and clarity in policies and regulations.
- Jul 22, 2015 03:00 PM IST
Kiran Mazumdar Shaw, CMD, Biocon says there is a need to protect interest and disallow monopolies like big pharma or big companies/ corporates that want to invest and take advantage of the Indian market.
- Apr 22, 2015 06:09 PM IST
Biocon will be offloading at least 10 percent of Syngene equity as it needs funds to support some of its R&D programmes.
- Apr 01, 2015 01:41 PM IST
Kiran Mazumdar Shaw, Chairperson and MD, Biocon also said that Syngene has good growth prospects and sound business plan and has a baseline valuation of Rs 3,800 crore.
- Mar 26, 2015 10:44 AM IST
Rubbishing concerns that the increasing FDA scrutiny of Indian pharma companieswas a case of "irrational clampdown", Biocon CMD Kiran Mazumdar-Shaw told CNBC-TV18 that the US regulator is mandating more stringent norms for companies across the world.
- Oct 29, 2014 03:02 PM IST
Biocon has launched INSUpen EZ, a second-generation insulin-delivery pen device, developed by Germany‘s Haselmeier. â€œThis is a low-cost pen, which will help us penetrate the market in a bigger way,â€ CMD Kiran Mazumdar-Shaw told CNBC-TV18‘s Ekta Batra and Nigel D‘Souza.
- Mar 07, 2014 03:27 PM IST
Biocon CMD Kiran Mazumdar-Shaw said the company‘s research efforts are focused on a number of programs that deliver drugs that women can benefit from.
- Dec 20, 2013 11:30 AM IST
Biocon has inked a pact with California-based Quark Pharma to co-develop medicines based on the emerging siRNA technology.
- Nov 25, 2013 10:18 AM IST
Kiran Mazumdar Shaw, CMD, Biocon says the nod is for India marketing rights but opens up huge opportunities as the cancer drug has a market of USD 6 billion worldwide.
- Feb 14, 2013 10:31 AM IST
Biocon, a global biopharmaceutical enterprise today entered into a licencing agreement with Mylan for three bio-generic insulin products. Kiran Mazumdar, CMD, Biocon, in an interview to CNBC-TV18, says that the company will receive licencing fees from Mylan, however, they will not receive any milestone payments.
- Nov 16, 2012 09:26 AM IST
Biotech major Biocon has signed an option agreement with Bristol-Myers Squibb Company for Biocon‘s IN-105, a prandial oral insulin product candidate.
- Jun 04, 2012 02:01 PM IST
Drug firm Abbott today opened its first nutrition research and development center in the country in collaboration with Biocon's subsidiary Syngene.
- Mar 13, 2012 10:50 AM IST
In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.
- Mar 12, 2012 09:59 PM IST
The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.
- Sep 24, 2011 04:25 PM IST
India's largest listed biotechnology firm Biocon's chairperson and managing director Kiran Mazumdar-Shaw is one of India's most successful entrepreneurs.
- Sep 14, 2011 12:04 PM IST
Biocon chief Kiran Mazumdar-Shaw says that the research division is set to benefit from the fall in the value of rupee. "That apart, Biocon will see margin improvement in exports due to the rate differential," she says.
- Jun 07, 2011 10:39 AM IST
Kiran Mazumdar, CMD, Biocon in an interview with CNBC-TV18 speaking about the same said that Optimer is planning to launch within the next three- four months. So, in the short-term Biocon will have some contribution to the bottom line from these supplies.